Rapport Therapeutics Financial Statements
NASDAQ: RAPPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
30.65+0.80 (+2.68%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 30.65 0.00%
Rapport Therapeutics revenue and earnings
Rapport Therapeutics reported a net loss of $111.5 million, compared with a loss of $78.3 million a year earlier. Diluted earnings per share came in at -$2.86.
Summary generated from market data by MetaCap's automated system. Methodology
Rapport Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Operating Expenses | 125.10M | 83.06M | 36.18M |
| Research & Development | 94.79M | 60.94M | 28.00M |
| Operating Income | -125.10M | -83.06M | -36.18M |
| Other Income (Expense) | 13.62M | 4.75M | 1.40M |
| Pretax Income | — | -78.31M | -34.78M |
| Income Tax | 0 | 0 | 10.00K |
| Net Income | -111.48M | -78.31M | -34.79M |
| Net Income growth (YoY) | — | — | — |
| EPS (Basic) | -2.86 | -3.78 | -23.10 |
| EPS (Diluted) | -2.86 | -3.78 | -23.10 |
| Shares Outstanding (Basic) | 38.93M | 20.74M | 1.51M |
| Shares Outstanding (Diluted) | 38.93M | 20.74M | 1.51M |
| EBITDA | -124.08M | -82.22M | -36.07M |
This table shows 3 annual periods of Rapport Therapeutics's income statement, from FY 2025 back to FY 2023, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow RAPP's reporting calendar. What is a income statement?